Can Fite Price To Sales vs. Price To Book

CANF Stock  USD 2.10  0.05  2.44%   
Based on the measurements of profitability obtained from Can Fite's financial statements, Can Fite Biopharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Can Fite's ability to earn profits and add value for shareholders.

Can Fite Price To Sales Ratio

12.14

The Can Fite's current Sales General And Administrative To Revenue is estimated to increase to 6.64, while Price To Sales Ratio is projected to decrease to 12.14. At this time, Can Fite's Net Interest Income is most likely to decrease significantly in the upcoming years. The Can Fite's current Change To Netincome is estimated to increase to about 730.5 K, while Accumulated Other Comprehensive Income is projected to decrease to roughly 963.6 K.
For Can Fite profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Can Fite to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Can Fite Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Can Fite's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Can Fite Biopharma over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.60)
Quarterly Revenue Growth
(0.19)
Return On Assets
(0.57)
Return On Equity
(1.58)
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Can Fite Biopharma Price To Book vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Can Fite's current stock value. Our valuation model uses many indicators to compare Can Fite value to that of its competitors to determine the firm's financial worth.
Can Fite Biopharma is rated below average in price to sales category among its peers. It is rated below average in price to book category among its peers fabricating about  0.25  of Price To Book per Price To Sales. The ratio of Price To Sales to Price To Book for Can Fite Biopharma is roughly  3.98 . At this time, Can Fite's Price To Sales Ratio is most likely to decrease significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Can Fite by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Can Price To Book vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Can Fite

P/S

 = 

MV Per Share

Revenue Per Share

 = 
20.05 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Can Fite

P/B

 = 

MV Per Share

BV Per Share

 = 
5.04 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Can Price To Book Comparison

Can Fite is currently under evaluation in price to book category among its peers.

Can Fite Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Can Fite, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Can Fite will eventually generate negative long term returns. The profitability progress is the general direction of Can Fite's change in net profit over the period of time. It can combine multiple indicators of Can Fite, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive IncomeM963.6 K
Operating Income-8.2 M-8.6 M
Income Before Tax-7.6 M-8 M
Total Other Income Expense Net561 K533 K
Net Loss-7.6 M-8 M
Income Tax Expense 1.00  0.95 
Net Loss-9 M-9.5 M
Net Loss-11.7 M-12.3 M
Interest Income506 K287.6 K
Net Interest Income726 K762.3 K
Change To Netincome695.8 K730.5 K
Net Loss(0.01)(0.01)
Income Quality 1.11  0.80 
Net Income Per E B T 0.93  0.79 

Can Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Can Fite. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Can Fite position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Can Fite's important profitability drivers and their relationship over time.

Use Can Fite in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Can Fite position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Can Fite will appreciate offsetting losses from the drop in the long position's value.

Can Fite Pair Trading

Can Fite Biopharma Pair Trading Analysis

The ability to find closely correlated positions to Can Fite could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Can Fite when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Can Fite - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Can Fite Biopharma to buy it.
The correlation of Can Fite is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Can Fite moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Can Fite Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Can Fite can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Can Fite position

In addition to having Can Fite in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Consumer Staples ETFs Thematic Idea Now

Consumer Staples ETFs
Consumer Staples ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Staples ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Staples ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:
Check out Trending Equities.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
To fully project Can Fite's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Can Fite Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Can Fite's income statement, its balance sheet, and the statement of cash flows.
Potential Can Fite investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Can Fite investors may work on each financial statement separately, they are all related. The changes in Can Fite's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Can Fite's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.